Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic
OBJECTIVE: To present the effectiveness of standard regimens under routine national conditions.
DESIGN: We reviewed all MDR-TB patients treated under routine conditions from 29 August 2006 to 30 June 2010, showing interim and final outcomes. Patients were treated with regimens that were standardised or individualised based on previously received second-line anti-tuberculosis drugs.
RESULTS: Population description and culture conversion data are reported for the 289 MDR-TB patients. The median patient age was 31 years. Most had failed first-line treatment (72.6%). Culture negativity was obtained within 4 months (median 2 months) in 78.6%. Among the 150 patients treated between 2006 and 2008, 74% had favourable results on standardised and 66% on individualised regimens (P = 0.211). The efficacy of the standardised and individualised regimens was respectively 92.8% and 81% (P = 0.056). The relapse rate was approximately 1%. A median of five drug side effects occurred per patient. More than 2 months to culture conversion and bilateral cavitation on chest X-ray were found to be unfavourable outcome risk factors.
CONCLUSIONS: Standardised MDR-TB regimens may be effective at the national level, even in resource-poor settings.
Keywords: Dominican Republic; MDR-TB; TB; multidrug-resistant tuberculosis; standardised treatment; tuberculosis
Document Type: Research Article
Affiliations: 1: Dominican Republic National Tuberculosis Programme, Santo Domingo, Dominican Republic 2: MDR-TB Unit, Department of Tuberculosis and HIV, International Union Against Tuberculosis and Lung Disease, Paris, France; and Departament de Pediatria, Ginecologia i Medicina Preventiva, Universitat Autònoma de Barcelona, Barcelona, Spain 3: MDR-TB Unit, Department of Tuberculosis and HIV, International Union Against Tuberculosis and Lung Disease, Paris, France; and Servicio de Neumología, Hospital General de Gran Canaria ‘Dr Negrin’, Las Palmas de Gran Canaria, Spain 4: Comité Nacional de Evaluación TB-MDR, Santo Domingo, Dominican Republic 5: Panamerican Health Organization, Washington DC, USA 6: Centros de Investigación Biomédica en Red de Epidemiología y Salud Pública, Barcelona, Spain; and Departament de Salut Pública, Universitat de Barcelona, Barcelona, Spain 7: Centros de Investigación Biomédica en Red de Epidemiología y Salud Pública, Barcelona, Spain
Publication date: 01 April 2013
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content